Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells’ Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway
Molecules · 2023
DOI: 10.3390/molecules28237776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Jinyue Duan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China. Hauptthemen laut MEDLINE: Colonic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Science and Technology Department, Graduate Innovation Fund of Jilin University, Technology Development Plan of Jilin Province.
Abstract (Originalsprache)
This study explored the role of lymphocyte antigen 6 family member D (LY6D) in colon cancer stem cells’ (CCSCs) proliferation and invasion. LY6D was knocked down using siRNA, and the down-regulation of LY6D was verified using Western blotting. After LY6D knockdown, CCSCs’ proliferation, stemness, and invasion were suppressed, whereas apoptosis was increased. Gene Ontology (GO) enrichment analysis revealed that the differentially expressed genes (DEGs) between siLY6D and the negative control groups were significantly enriched in the cell–substrate adherens junction, focal adhesion, and cell–substrate junction terms. Meanwhile, the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the DEGs were significantly enriched in the MAPK pathway. In addition, Western blotting results showed that pBRAF and pERK1/2, cascade kinases of the MAPK pathway, were significantly down-regulated after LY6D knockdown. In addition, nude mice xenograft experiments showed that the siLY6D treatment decreased tumor sizes and weights and improved tumor-bearing mice survival rates compared with the control group. In conclusion, these findings indicate that LY6D, which is highly expressed in CCSCs, is a key factor involved in tumor growth and development and might be a potential cancer marker and therapeutic target for colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
- VA Palo Alto Health Care System, Medical School, Stanford University, Palo Alto, CA 94304, USA.
ORCID-Profile: Yi Wang, Changhao Fu, Zhongyi Cong, Manman Su
Förderung
- Jilin Province Science and Technology Department
- Graduate Innovation Fund of Jilin University
- Technology Development Plan of Jilin Province
Zitieren
APA
Duan, J., Wang, Y., Chen, Y., Wang, Y., Li, Q., Liu, J., Fu, C., Cao, C., Cong, Z., & Su, M. (2023). Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells’ Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway. Molecules. https://doi.org/10.3390/molecules28237776
Vancouver
Duan J, Wang Y, Chen Y, Wang Y, Li Q, Liu J, et al. Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells’ Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway. Molecules. 2023. doi:10.3390/molecules28237776
BibTeX
@article{Duan2023,
author = {Duan, Jinyue and Wang, Yi and Chen, Yuanyuan and Wang, Yujue and Li, Qisen and Liu, Jinrui and Fu, Changhao and Cao, Chenyu and Cong, Zhongyi and Su, Manman},
title = {Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells’ Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28237776}
}
EUVIMED